A GLP-1 agonist will address the insulin and appetite problem
The exendin-4 C-terminal tail, which consists of nine amino acid residues, enhances the binding affinity of exendin-4 to the N-terminal extracellular domain (ECD) of GLP1R [18]
The potential benefits of GLP-1s include: Weight loss Obesity management Reduced cravings or food noise Improved lipid disorders Improved fatty liver disease Reduced risk of kidney disease Delayed progression of diabetes-related nephropathy Reduced risk of cardiovascular disease (CVD) Lower risk of stroke Ongoing studies are exploring the effectiveness of GLP-1 medications for other conditions, such as polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD)
There are also some lesser-discussed weight-loss medications that may come with very different price points
This was attributed to an increase in the activity of superoxide dismutase, glutathione peroxidase, and glutathione S-transferase, while also reducing malondialdehyde and ROS content (Honardoust et al., 2021)
I still have to eat, I love food